Compare Neurocrine Biosciences Inc (NBIX) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs TORM plc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while TORM plc trades at $29.89 (market cap $2.99B). The key difference: Neurocrine Biosciences Inc is far larger — about 5.8× TORM plc's market cap, and TORM plc pays a 9.62% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | TRMD | |
|---|---|---|
Market Cap | $17.40B | $2.99B |
Sector | Health | Technology |
52-Week High | $180.55 | $34.87 |
52-Week Low | $123.10 | $17.50 |
Enterprise Value | $16.49B | $3.88B |
Dividend Yield | — | 9.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
TRMD trades at $29.08, up 2.21% today, with a bullish technical signal from moving averages. The company reported strong 2025 results with $1.34B revenue and $285.3M net income, though recent Q1 2026 EPS missed expectations. Valuation ratios appear attractive with a P/E of 8.54 and P/S of 2.08. Recent news highlights strong cash generation and a potential merger with Hafnia.
The outlook is positive with 100% analyst buy ratings and a near 9% dividend yield. Key risks include earnings volatility and market exposure, but disciplined capital allocation and high profitability margins support upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
